Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAMAL: ICS/LABA Reduction in Benralizumab-Treated Asthma
NCT04159519Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of benralizumab in eosinophilic asthma (EA) (2 arms), sponsored by AstraZeneca. Primary endpoint: Proportion of Patients Who Reduced Their Symbicort® Maintenance Dose at the End of the Reduction Period at 32 weeks. Started Jul 2020; status: completed.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04159519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159519.